McKesson traded at $827.14 this Monday August 3rd, decreasing $29.05 or 3.39 percent since the previous trading session. Looking back, over the last four weeks, McKesson lost 5.47 percent. Over the last 12 months, its price rose by 16.34 percent. Looking ahead, we forecast McKesson to be priced at 838.04 by the end of this quarter and at 785.86 in one year, according to Trading Economics global macro models projections and analysts expectations.
McKesson Corporation is focused distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools. The Company’s segments include U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment provides distribution and logistics services for branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. The International segment provides distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. RxTS segment combines its technologies, including CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, to serve its biopharma and life sciences partners and patients.